I have a confession to make: I’m fascinated by failure. Not in a morbid, schadenfreude sort of way, but in the way one might study an iceberg—not for the visible peak but for the vast, hidden bulk beneath. And in no industry is that unseen mass more significant

Mentoring: It’s Not Just a LinkedIn Title Mentoring is having a moment. If you’ve scrolled through LinkedIn recently, you’ve probably noticed an explosion of people adding “mentor” to their titles. It sounds noble, even glamorous—guiding the next generation, shaping the future, giving back. But let’s

Overall survival (OS) has long been considered the gold standard in oncology trials. Defined as the time from treatment initiation until death from any cause, OS provides a direct and intuitive measure of a therapy's impact on patient longevity. However, as the costs of oncology treatments skyrocket, even

Probability of Pricing and Access Success (PPAS) is an emerging metric that evaluates the likelihood of a drug achieving favorable pricing and market access post-approval. Unlike traditional metrics such as Probability of Success (POS) or Probability of Launch (POL), PPAS explicitly incorporates factors often neglected in drug development analyses—

Probability of Technical Success (PTS) is a metric that evaluates the likelihood that a drug candidate will successfully navigate clinical trials. Unlike broader metrics such as Probability of Success (POS) or Probability of Launch (POL), PTS focuses narrowly on the technical aspects of clinical development, including efficacy, safety, and adherence

The MSCI World Pharmaceuticals, Biotechnology, and Life Sciences Index (USD) is a key benchmark for the biotech and pharmaceutical industry. Comprising 72 large- and mid-cap stocks across 23 markets, this index provides a perspective on companies involved in drug development, biotechnology innovation, and life sciences tools and services. Index

Killing a project is easy. There’s a laundry list of reasons why something “shouldn’t move forward”: it’s too expensive, not aligned with strategy, lacks clear ROI, or simply isn’t the “right time.” Most organizations are primed to find these flaws—whether it’s a risk-averse

LinkedIn profiles boasting titles like ex-McKinsey, ex-Bain, ex-Novartis, or ex-Roche. It’s as if these professionals are collecting exes, not in their personal lives (well, hopefully), but in their résumés, brandishing them like badges of honor.

In European boardrooms, where modesty often masquerades as pragmatism, it is rare for a leader to sound the alarm with the urgency of Mario Draghi. His latest report on the EU pharmaceutical sector paints a stark picture: Europe, once a stalwart in global healthcare, is limping behind its competitors. Without

The Problem with Probability of Success (POS) in Biotech and Pharma Probability of Success (POS) is a widely used metric in biotech and pharma, offering a single probability that a drug candidate will successfully navigate the entire development process, from discovery through preclinical and clinical trials to regulatory approval and